CureVac (CVAC) has released an update. CureVac is set to unveil promising new data from its mRNA-based cancer vaccine study at the upcoming mRNA Health Conference, showcasing significant ...

CureVac (CVAC) announced that new and updated data will be shared in two oral presentations and four posters at the 12th International mRNA Health Conference, taking place in Boston, Massachusetts ...

With the possibility of Robert F. Kennedy, Jr. being involved in health policy in the next administration, vaccination – ...

They found that mRNA vaccines that target C. diff cells and the toxins they produce generated a lasting immune response in ...

The article by Sarfaraz K. Niazi, PhD, argues that the FDA’s classification of future copies of messenger RNA (mRNA) products ...

The Nucleic Acid Therapeutics Initiative (NATi), a national platform hosted by the Agency for Science, Technology and Research (A*STAR), officially launched the non-GMP NATi mRNA BioFoundry today.

As a key player in protein synthesis, mRNA technology is transforming therapeutics, offering solutions for cancer, genetic disorders, and regenerative medicine.

Like humans and other complex multicellular organisms, single-celled bacteria can fall ill and fight off viral infections. A ...

mRNA vaccines provide similar protection from allergic sensitization as DNA vaccines, based on Th1 immunity. Induction of a subtle Th1 bias is sufficient as subsequent allergen contact boosts and ...

CureVac and partner GSK are, meanwhile, also developing an mRNA-based flu vaccine, but are a little further back in development, as their shot is in phase 1 testing.

GSK has filed a pair of lawsuits against Moderna, claiming infringement of patents covering mRNA vaccines for COVID-19 and respiratory syncytial virus (RSV). According to court documents ...

Ancient Viral DNA in the Human Genome Linked to Multiple Sclerosis and Amyotrophic Lateral Sclerosis Oct. 21, 2024 — New research has revealed a connection between ancient viral DNA embedded in ...